Courtesy of Benzinga.
In a report published Thursday, Barrington Research analyst Michael Petusky assumed coverage on Haemonetics Corporation (NYSE: HAE) with an Outperform rating and $46.00 price target.
In the report, Barrington Research noted, “Our price target is $46 and we arrive at our target by attaching a 11x multiple to our 2016 adjusted EBITDA estimate of $245.0 million and a 10.3x multiple to our 2017 adjusted EBITDA estimate of $262.7.0 million. We feel a 10-12x multiple range is appropriate for companies like Haemonetics whose businesses contains elements of both a devices company, as well as a healthcare services business.”
Haemonetics closed on Wednesday at $36.41.
Latest Ratings for HAE
Date | Firm | Action | From | To |
---|---|---|---|---|
Nov 2014 | Barrington Research | Assumes | Outperform | |
May 2014 | Jefferies | Maintains | Buy | |
Apr 2014 | Jefferies | Maintains | Buy |
View More Analyst Ratings for HAE
View the Latest Analyst Ratings
Posted-In: Barrington Research Michael PetuskyAnalyst Color Initiation Analyst Ratings